Oxurion provides clarification on the agenda of the extraordinary general shareholders’ meeting to be held on 24 July 2024 July 11, 20240CommentsEN NL Read More
Oxurion signs a Letter of Intent and enters into exclusive negotiations to potentially acquire a pioneering French CRO in stem cell production July 8, 20240CommentsEN NL FR Read More
Oxurion announces the results of the Extraordinary General Meeting (EGM) held on 4 July 2024 and convenes a new EGM on 24 July 2024 July 4, 20240CommentsEN NL FR Read More
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC June 7, 20240CommentsEN NL Read More
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC May 27, 20240CommentsEN NL Read More
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas May 23, 20240CommentsEN NL Read More
Oxurion Announces Results on the Annual Shareholders’ Meeting of 16 May 2024 May 23, 20240CommentsEN NL Read More
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC May 16, 20240CommentsEN NL Read More
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas May 14, 20240CommentsEN NL Read More
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC May 13, 20240CommentsEN NL Read More
Important Advances in Oxurion’s R&D Program on Geographic Atrophy secondary to AMD May 6, 20240CommentsEN NL FR Read More
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC April 25, 20240CommentsEN NL Read More
Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC April 11, 20240CommentsEN NL Read More
Oxurion Receives EUR 450,000 in the framework of the Atlas Funding Program : Eleventh tranche fully issued and paid-up April 10, 20240CommentsEN FR Read More
Postponement Annual Shareholders Meeting – Amendment financial calendar April 5, 20240CommentsEN NL Read More
